| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Biopathological Science, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan;
Department of Immunology, National Institute of Neuroscience, Tokyo, Japan;
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232;
Department of Pathology, University of Florida College of Medicine, Gainesville, FL 32610; and
¶ Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan
NKT cells are a unique immunoregulatory T cell population that produces large amounts of cytokines. We have investigated whether stimulation of host NKT cells could modulate acute graft-vs-host disease (GVHD) in mice. Injection of the synthetic NKT cell ligand 
-galactosylceramide (-GalCer) to recipient mice on day 0 following allogeneic bone marrow transplantation promoted Th2 polarization of donor T cells and a dramatic reduction of serum TNF-, a critical mediator of GVHD. A single injection of -GalCer to recipient mice significantly reduced morbidity and mortality of GVHD. However, the same treatment was unable to confer protection against GVHD in NKT cell-deficient CD1d knockout (CD1d–/–) or IL-4–/– recipient mice or when STAT6–/– mice were used as donors, indicating the critical role of host NKT cells, host production of IL-4, and Th2 cytokine responses mediated by donor T cells on the protective effects of -GalCer against GVHD. Thus, stimulation of host NKT cells through administration of NKT ligand can regulate acute GVHD by inducing Th2 polarization of donor T cells via STAT6-dependent mechanisms and might represent a novel strategy for prevention of acute GVHD.
This article has been cited by other articles:
|
|
 |
|
  R. D. Kuns, E. S. Morris, K. P. A. MacDonald, K. A. Markey, H. M. Morris, N. C. Raffelt, T. Banovic, A. L. J. Don, V. Rowe, A. C. Burman, et al. Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after {alpha}-galactosylceramide administration Blood, June 4, 2009; 113(23): 5999 - 6010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Pillai, T. I. George, S. Dutt, and S. Strober Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease Blood, April 30, 2009; 113(18): 4458 - 4467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Koyama, D. Hashimoto, K. Aoyama, K.-i. Matsuoka, K. Karube, H. Niiro, M. Harada, M. Tanimoto, K. Akashi, and T. Teshima Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells Blood, February 26, 2009; 113(9): 2088 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Aoyama, M. Koyama, K.-i. Matsuoka, D. Hashimoto, T. Ichinohe, M. Harada, K. Akashi, M. Tanimoto, and T. Teshima Improved outcome of allogeneic bone marrow transplantation due to breastfeeding-induced tolerance to maternal antigens Blood, February 19, 2009; 113(8): 1829 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Kim, E. Y. Choi, and D. H. Chung Donor Bone Marrow Type II (Non-V{alpha}14J{alpha}18 CD1d-Restricted) NKT Cells Suppress Graft-Versus-Host Disease by Producing IFN-{gamma} and IL-4 J. Immunol., November 15, 2007; 179(10): 6579 - 6587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Pillai, T. I. George, S. Dutt, P. Teo, and S. Strober Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation J. Immunol., May 15, 2007; 178(10): 6242 - 6251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sakoda, D. Hashimoto, S. Asakura, K. Takeuchi, M. Harada, M. Tanimoto, and T. Teshima Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease Blood, February 15, 2007; 109(4): 1756 - 1764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Morris, K. P. A. MacDonald, and G. R. Hill Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood, May 1, 2006; 107(9): 3430 - 3435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Matsuoka, T. Ichinohe, D. Hashimoto, S. Asakura, M. Tanimoto, and T. Teshima Fetal tolerance to maternal antigens improves the outcome of allogeneic bone marrow transplantation by a CD4+CD25+ T-cell-dependent mechanism Blood, January 1, 2006; 107(1): 404 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Patterson, I. Kotsianidis, A. Almeida, M. Politou, A. Rahemtulla, B. Matthew, R. R. Schmidt, V. Cerundolo, I. A. G. Roberts, and A. Karadimitris Human Invariant NKT Cells Are Required for Effective In Vitro Alloresponses J. Immunol., October 15, 2005; 175(8): 5087 - 5094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R Blazar and W. J Murphy Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD) Phil Trans R Soc B, September 29, 2005; 360(1461): 1747 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Haraguchi, T. Takahashi, A. Matsumoto, T. Asai, Y. Kanda, M. Kurokawa, S. Ogawa, H. Oda, M. Taniguchi, H. Hirai, et al. Host-Residual Invariant NK T Cells Attenuate Graft-versus-Host Immunity J. Immunol., July 15, 2005; 175(2): 1320 - 1328. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
